Bronchiolitis obliterans syndrome: The final frontier for lung transplantation

Chest

Volumn 140, Issue 2, 2011, Pages 502-508

  Todd, Jamie L ^a   Palmer, Scott M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOANTIBODY; BORTEZOMIB; CALCINEURIN INHIBITOR; CD14 ANTIGEN; CYCLOSPORIN; GAMMA INTERFERON; HLA ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; PATTERN RECOGNITION RECEPTOR; PLACEBO; RITUXIMAB; TACROLIMUS; THYMOCYTE ANTIBODY; TOLL LIKE RECEPTOR 4;

AIRWAY OBSTRUCTION; ALLOIMMUNITY; AUTOIMMUNITY; BRONCHIOLITIS OBLITERANS; CELL ACTIVATION; CHRONIC ALLOGRAFT NEPHROPATHY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG TARGETING; GRAFT INFECTION; GRAFT SURVIVAL; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; LYMPHOCYTIC INFILTRATION; MEDICAL RESEARCH; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; RESPIRATORY TRACT FIBROSIS; REVIEW; RISK ASSESSMENT; STOMACH FUNDOPLICATION; T CELL DEPLETION; T LYMPHOCYTE; TH1 CELL;

EID: 80051491362     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.10-2838     Document Type: Review

References (50)

1. Burke CM, Theodore J, Dawkins KD, et al. Post-transplant obliterative bronchiolitis and other late lung sequelae in human heart-lung transplantation. Chest. 1984;86(6):824-829. (Pubitemid 15181406)
2. Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21(3):297-310. (Pubitemid 34224094)
3. Christie JD, Edwards LB, Aurora P, et al. Registry of the Inter national Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report - 2008. J Heart Lung Transplant. 2008;27(9):957-969.
4. Finlen Copeland CA, Snyder LD, Zaas DW, Turbyfill WJ, Davis WA, Palmer SM. Survival after bronchiolitis obliterans syndrome among bilateral lung transplant recipients. Am J Respir Crit Care Med. 2010;182(6):784-789.
5. Gerbase MW, Soccal PM, Spiliopoulos A, Nicod LP, Rochat T. Long-term health-related quality of life and walking capacity of lung recipients with and without bronchiolitis obliterans syndrome. J Heart Lung Transplant. 2008;27(8):898-904.
6. van den Berg JW, Geertsma A, van der Bij W, et al. Bronchiolitis obliterans syndrome after lung transplantation and health-related quality of life. Am J Respir Crit Care Med. 2000;161(6):1937-1941. (Pubitemid 30418133)
7. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21(2):271-281. (Pubitemid 34130545)
8. Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, Malouf MA. Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med. 2008;177(9):1033-1040. (Pubitemid 351717599)
9. Zuo X-J, Matsumura Y, Prehn J, et al. Cytokine gene expression in rejecting and tolerant rat lung allograft models: analysis by RT-PCR. Transpl Immunol. 1995;3(2):151-161.
10. Jaramillo A, Fernández FG, Kuo EY, Trulock EP, Patterson GA, Mohanakumar T. Immune mechanisms in the pathogenesis of bronchiolitis obliterans syndrome after lung transplantation. Pediatr Transplant. 2005;9(1):84-93. (Pubitemid 40238970)
11. Mauck KA, Hosenpud JD. The bronchial epithelium: a potential allogeneic target for chronic rejection after lung transplantation . J Heart Lung Transplant. 1996;15(7):709-714. (Pubitemid 26268890)
12. McDyer JF. Human and murine obliterative bronchiolitis in transplant. Proc Am Thorac Soc. 2007;4(1):37-43. (Pubitemid 46067561)
13. Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant. 2010;10(2):382-388.
14. Reams BD, Musselwhite LW, Zaas DW, et al. Alemtuzumab in the treatment of refractory acute rejection and bronchiolitis obliterans syndrome after human lung transplantation. Am J Transplant. 2007;7(12):2802-2808. (Pubitemid 350045775)
15. Iacono AT, Johnson BA, Grgurich WF, et al. A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006;354(2):141-150. (Pubitemid 43076711)
16. Martinu T, Chen DF, Palmer SM. Acute rejection and humoral sensitization in lung transplant recipients. Proc Am Thorac Soc. 2009;6(1):54-65.
17. Glanville AR. Antibody-mediated rejection in lung transplantation: myth or reality? J Heart Lung Transplant. 2010;29(4):395-400.
18. Palmer SM, Davis RD, Hadjiliadis D, et al. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation. 2002;74(6):799-804.
19. Jaramillo A, Smith MA, Phelan D, et al. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation . Transplantation. 1999;67(8):1155-1161. (Pubitemid 29205579)
20. Smith MA, Sundaresan S, Mohanakumar T, et al. Effect of development of antibodies to HLA and cytomegalovirus mismatch on lung transplantation survival and development of bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg. 1998;116(5):812-820. (Pubitemid 28499176)
21. Jaramillo A, Smith CR, Maruyama T, Zhang L, Patterson GA, Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol. 2003;64(5):521-529. (Pubitemid 36504691)
22. Fukami N, Ramachandran S, Saini D, et al. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol. 2009;182(1):309-318.
23. Magro CM, Ross P Jr, Kelsey M, Waldman WJ, Pope- Harman A. Association of humoral immunity and bronchiolitis obliterans syndrome. Am J Transplant. 2003;3(9):1155-1166. (Pubitemid 37064556)
24. Jaramillo A, Naziruddin B, Zhang L, et al. Activation of human airway epithelial cells by non-HLA antibodies developed after lung transplantation: a potential etiological factor for bronchiolitis obliterans syndrome. Transplantation. 2001;71(7):966-976. (Pubitemid 32417360)
25. Hachem RR, Yusen RD, Meyers BF, et al. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant. 2010;29(9):973-980.
26. Lemy A, Toungouz M, Abramowicz D. Bortezomib: a new player in pre-and post-transplant desensitization? Nephrol Dial Transplant. 2010;25(11):3480-3489.
27. Ashton-Chess J, Mai HL, Jovanovic V, et al. Immunoproteasome beta subunit 10 is increased in chronic antibodymediated rejection. Kidney Int. 2010;77(10):880-890.
28. Neumann J, Tarrasconi H, Bortolotto A, et al. Acute humoral rejection in a lung recipient: reversion with bortezomib. Transplantation. 2010;89(1):125-126.
29. Sumpter TL, Wilkes DS. Role of autoimmunity in organ allograft rejection: a focus on immunity to type V collagen in the pathogenesis of lung transplant rejection. Am J Physiol Lung Cell Mol Physiol. 2004;286(6):L1129-L1139. (Pubitemid 38656647)
30. Madri JA, Furthmayr H. Collagen polymorphism in the lung. An immunochemical study of pulmonary fibrosis. Hum Pathol. 1980;11(4):353-366. (Pubitemid 10032506)
31. Wilkes DS, Heidler KM, Bowen LK, et al. Allogeneic bronchoalveolar lavage cells induce the histology of acute lung allograft rejection, and deposition of IgG2a in recipient murine lungs. J Immunol. 1995;155(5):2775-2783.
32. Burlingham WJ, Love RB, Jankowska-Gan E, et al. IL-17-dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. J Clin Invest. 2007;117(11):3498-3506. (Pubitemid 350097005)
33. Vanaudenaerde BM, De Vleeschauwer SI, Vos R, et al. The role of the IL23/IL17 axis in bronchiolitis obliterans syndrome after lung transplantation. Am J Transplant. 2008;8(9):1911-1920.
34. Goers TA, Ramachandran S, Aloush A, Trulock E, Patterson GA, Mohanakumar T. De novo production of K-alpha1 tubulin-specific antibodies: role in chronic lung allograft rejection. J Immunol. 2008;180(7):4487-4494.
35. Hueber W, Patel DD, Dryja T, et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2(52):52ra72.
36. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001;1(2):135-145. (Pubitemid 33741967)
37. Barton GM, Medzhitov R. Control of adaptive immune responses by Toll-like receptors. Curr Opin Immunol. 2002;14(3):380-383. (Pubitemid 34327982)
38. Kuo E, Bharat A, Goers T, et al. Respiratory viral infection in obliterative airway disease after orthotopic tracheal transplantation . Ann Thorac Surg. 2006;82(3):1043-1050.
39. Palmer SM, Burch LH, Trindade AJ, et al. Innate immunity influences long-term outcomes after human lung transplant. Am J Respir Crit Care Med. 2005;171(7):780-785. (Pubitemid 40471150)
40. Palmer SM, Klimecki W, Yu L, et al. Genetic regulation of rejection and survival following human lung transplantation by the innate immune receptor CD14. Am J Transplant. 2007;7(3):693-699. (Pubitemid 46376452)
41. Garantziotis S, Palmer SM, Snyder LD, et al. Alloimmune lung injury induced by local innate immune activa tion through inhaled lipopolysaccharide. Transplantation. 2007;84(8):1012-1019. (Pubitemid 350287382)
42. Goldstein DR, Tesar BM, Akira S, Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest. 2003;111(10):1571-1578. (Pubitemid 38063290)
43. Weigt SS, Elashoff RM, Huang C, et al. Aspergillus colonization of the lung allograft is a risk factor for bronchiolitis obliterans syndrome. Am J Transplant. 2009;9(8):1903-1911.
44. Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection-myth or reality? Am J Transplant. 2003;3(3):245-249. (Pubitemid 36407040)
45. Snyder LD, Finlen-Copeland CA, Turbyfill WJ, Howell D, Willner DA, Palmer SM. Cytomegalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation . Am J Respir Crit Care Med. 2010;181(12):1391-1396.
46. Blondeau K, Mertens V, Vanaudenaerde BA, et al. Gastrooesophageal reflux and gastric aspiration in lung transplant patients with or without chronic rejection. Eur Respir J. 2008;31(4):707-713.
47. Wu H, Ma J, Wang P, et al. HMGB1 contributes to kidney ischemia reperfusion injury. J Am Soc Nephrol. 2010;21(11):1878-1890.
48. Oshansky CM, Krunkosky TM, Barber J, Jones LP, Tripp RA. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol. 2009;22(3):147-161.
49. Cantu E III, Appel JZ III, Hartwig MG, et al. J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004;78(4):1142-1151. (Pubitemid 39303826)
50. Davis RD Jr, Lau CL, Eubanks S, et al. Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation. J Thorac Cardiovasc Surg. 2003;125(3):533-542. (Pubitemid 36373899)